WuXi AppTec– tag –
-
Digital Biomanufacturing Market Projected to Reach $66.14 Billion by 2034, Driven by Automation and AI: Market Research Report
Fortune Business Insights Global Overview This article summarizes a Digital Biomanufacturing Market research report from Fortune Business Insights. The report projects the digital biomanufacturing market will reach $66.14 billion by 2034... -
Pharmaceutical CDMO Market Report: Capital Investments and Advanced Therapies Drive Growth
Global Market Insights Global Overview This article provides an overview of the Pharmaceutical CDMO Market research report published by Global Market Insights. The report highlights significant capital investments and major expansions wi... -
Biologics CDMO Market Competitive Landscape Report: Lonza, Samsung Biologics, and WuXi Biologics Drive Growth
National Law Review USA Overview This article summarizes a report on the competitive landscape and growth drivers of the biologics CDMO market. Key players include Lonza Group Ltd, Samsung Biologics Co Ltd, WuXi Biologics Cayman Inc, The... -
WuXi Biologics Suzhou BioSafety Testing Center Secures Fourth EMA GMP Certification, Enabling 19 Commercial Products for European Market
WuXi Biologics China Overview WuXi Biologics' Suzhou BioSafety Testing Center has successfully renewed its European Medicines Agency (EMA) GMP certification for the fourth time. This accreditation enables the center to support quality te... -
WuXi Biologics Completes and Prepares for Operation of New Antibody-Drug Conjugate (ADC) Manufacturing Facility
WuXi Biologics Press Release China Overview WuXi Biologics announced the successful completion and readiness for operation of its new integrated Antibody-Drug Conjugate (ADC) manufacturing facility. This expansion significantly enhances ... -
Top 20 Biomanufacturing and CDMO Providers for 2026: Driving Innovation in Biopharma Production
Healthcare Ranking USA Overview The 2026 ranking of top biomanufacturing and Contract Development and Manufacturing Organization (CDMO) providers highlights industry leaders such as Lonza, Samsung Biologics, WuXi Biologics, and Thermo Fi... -
Regulatory & Policy Shifts Reshape Global Biologics Manufacturing Strategy: Focus on EU Reform, UK Decentralization, and US Tariffs
IMAPAC UK Overview Regulatory and policy shifts, including EU Pharma Reform, UK decentralized manufacturing initiatives, and U.S. tariffs, are fundamentally reshaping global biologics manufacturing strategies. Notably, the UK has establi... -
WuXi Biologics Intensifies Focus on South Korea to Bolster K-Biotech Partnerships Amid US Pressure
BioCentury (Chosun Biz) South Korea Overview WuXi Biologics is expanding its sales efforts in South Korea, actively targeting K-biotech companies amidst increasing U.S. legislative scrutiny on Chinese biotech firms. As a major global Con... -
WuXi Biologics Shanghai Drug Product Facility Achieves GMP Release, Expands Global Capacity
Contract Pharma China Overview WuXi Biologics' Drug Product Facility 15 (DP15) in Shanghai secured Good Manufacturing Practice (GMP) release in April 2026, becoming its 18th operational drug product facility globally. This state-of-the-a... -
WuXi’s Integrated CRDMO Model: Powering Global Biopharma Innovation and Its Evolving Impact
ChinaTalk USA Overview This article from ChinaTalk analyzes WuXi Group's dominant position within the biotechnology industry, particularly its comprehensive Contract Research, Development, and Manufacturing Organization (CRDMO) model. It...
